Currently, a class of drugs called receptor tyrosine kinase inhibitors (TKIs) have been heavily investigated in patients with FLT3-ITD positive AML, and have demonstrated promising results in clinical trials. The gene discussed is FLT3; the disease is acute myeloid leukemia.